Abstract: [Abstract] Objective To explore effects of serum soluble OX40 ligand (sOX40L), matrix metalloproteinase-9 (MMP-9) in patients with acute coronary syndromes (ACS) by rosuvastatin with different doses. Methods 60 patients with ACS were evenly devided into 20mg rosuvastatin treatment group (20mg group) and 10mg rosuvastatin treatment group (10mg group) at random, and 20 healthy volunteers were randomly assigned to control group. Serum concentrations of sOX40L, MMP-9 among above three groups were measured and analyzed before and after treatment. Results After two weeks’ treatment with rosuvastatin, serum concentrations of sOX40L, MMP-9 in patients of two treatment groups decreased significantly compared with pre-treatment (P<0.01). Moreover, the levels of sOX40L, MMP-9 in patients of 20mg group were lower than those in patients of 10mg group after two weeks’ treatment with rosuvastatin(P<0.05). Conclusion Larger doses of rosuvastatin may decrease the degradation of extraceller matrix of coronary atherosclerotic plaque and inflammatory reaction, stabilize coronary atherosclerotic vulnerable plaque when being used to treat patients with ACS, and can play a important role in improving prognosis of patients with ACS.

Key words: rosuvastatin, acute coronary syndromes, soluble OX40 ligand, matrix metalloproteinase-9